Although the molecular mechanism whereby inhibition of CDK4/6 inhibition impacts BRAF/MEK inhibition remains to be further investigated, we observed that simultaneous and subsequent treatment of palbociclib and SOC therapy in our BRAFV600E-mutant PDTXs significantly sustained tumor growth inhibition superior to SOC or single agent palbociclib . The gene discussed is BRAF; the disease is neoplasm.